Physician profile
Derek Everett Wells
NPI 1407209471
$4,338.73
in general payments reported to CMS, 2019-2025
21 companies · $682 in 2025
The $682 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $447 · 2023: $1,659 · 2024: $1,550 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,891.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,242.28 | 2022-2025 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,135.24 | 2022-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $343.46 | 2023-2024 | Dupixent |
| Amgen INC. | $315.38 | 2023-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.72 | 2022-2024 | Ofev |
| Genzyme Corporation | $226.99 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $178.21 | 2023-2025 | Glassia, Cuvitru |
| Insmed, INC. | $156.50 | 2023-2025 | Arikayce |
| Mylan Specialty L.P. | $102.23 | 2023-2024 | Yupelri |
| Pulmonx Corporation | $58.36 | 2023-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Ani Pharmaceuticals, INC. | $49.44 | 2024 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $47.23 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $43.91 | 2023-2024 | Xolair |
| Viatris Specialty LLC | $36.18 | 2025 | Yupelri |
| Harmony Biosciences LLC | $24.91 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $23.67 | 2023 | Illumisite |
| Inogen, INC. | $22.14 | 2025 | |
| Philips North America LLC | $21.83 | 2024 | (Ak6) Vest Therapy |
| United Therapeutics Corporation | $21.77 | 2025 | Tyvaso |
| Electromed, INC. | $19.67 | 2025 | Smartvest |
| Grifols USA, LLC | $17.61 | 2023 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.